Phase 1 Rheumatoid Arthritis Trial, Recruiting NCT07284797 Sponsor: Xencor, Inc. Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 1 Rheumatoid Arthritis Trial, Recruiting

NCT07284797
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults who are in good general health (for the healthy participant group)
  • Adults who have been diagnosed with idiopathic inflammatory myopathy (a condition where the immune system attacks the muscles), based on specific 2017 classification criteria used by rheumatology organisations
  • Adults who have been diagnosed with systemic sclerosis (a condition affecting the skin and internal organs), based on specific 2013 classification criteria used by rheumatology organisations
  • Adults who have been diagnosed with Sjögren's disease (a condition that commonly causes dry eyes and dry mouth), based on specific 2016 classification criteria used by rheumatology organisations
  • All participants must use highly effective methods of contraception during the trial

Who may not be able to join:

  • People who have had major surgery in the 12 weeks before the study starts, or who have planned major surgery during the study period
  • People who have frequent infections or a current significant infection
  • People who have active tuberculosis (TB), or a latent (inactive) TB infection that has not been treated
  • People who currently have cancer, or who have had cancer or a disease affecting the lymph system within the past 5 years
  • People who have a heart, lung, kidney, liver, hormonal, or digestive system condition that is not well controlled

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mark Osterman, MD, MSCE, Xencor, Inc.

Australian sites

Xencor Investigative Site, Melbourne,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Xencor, Inc.
Registry
ClinicalTrials.gov
Start date
24 February 2026
Est. completion
1 October 2028

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov